RT Journal Article
SR Electronic
T1 144 Ovarian carcinoma long-term survivors: a large single center study at the tübingen university women’s hospital
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A63
OP A63
DO 10.1136/ijgc-2020-IGCS.124
VO 30
IS Suppl 3
A1 S Mittelstadt
A1 M Grube
A1 T Engler
A1 CB Walter
A1 E Oberlechner
A1 J Pasternak
A1 U Hurst
A1 B Krämer
A1 E Grischke
A1 SY Brucker
A1 AK Fischer
A1 A Staebler
A1 A Hartkopf
A1 S Kommoss
YR 2020
UL http://ijgc.bmj.com/content/30/Suppl_3/A63.1.abstract
AB Introduction/Objectives Most ovarian carcinoma patients present with advanced-stage disease and outcome is fatal in many cases. However, the biological behavior of ovarian carcinoma can be quite variable and long-term survival is reported in up to 30% of patients. It is the aim of this project to identify characteristics associated with long-term survival.Methods Patients diagnosed with ovarian carcinoma between 2000 and 2012 were identified and follow-up data was collected. In patients who survived for at least 8 years a detailed chart review was performed.Results A total of n=749 patients with adequate follow-up was identified, of which n=225 (29%) were alive for at least 8 years after diagnosis. Median follow-up was 11.7 years. Median age at diagnosis was 53.5 years. 57% were diagnosed in advanced stage (≥FIGO IIB). Histotyp was found to be high-grade serous in 53%, low-grade serous in 7.9%, mucinous in 7.4%, clear cell in 3.7% and endometrioid in 20% of patients. Median progression free survival was 5.0 years in early, and 2.8 years in advanced-stage patients.Conclusion Despite ovarian carcinoma being perceived as a highly fatal disease, long-term survival is observed in a substantial number of patients and is not limited to early-stage or low-risk disease. Although prognostic factors are well established, further research of patient characteristics, genetic features and treatment modalities will help to better understand factors contributing to long-term survival. We encourage the scientific community to be aware of this special patient group, which may be key to improving our daily approach to ovarian carcinoma patients.